Advanced search×

Placental growth factor upregulation is a host response to antiangiogenic therapy.

Rebecca G RG Bagley, Yi Y Ren, William W Weber, Min M Yao, Leslie L Kurtzberg, Jason J Pinckney, Dinesh D Bangari, Cokey C Nguyen, William W Brondyk, Johanne J Kaplan, and Beverly A BA Teicher

Clin Cancer Res 17(5):976-88 (2011) PMID 21343374

Placental growth factor (PlGF) is an angiogenic protein. Upregulation of PlGF has been observed in the clinic following antiangiogenic regimens targeting the VEGF pathway. PlGF has been proposed as a therapeutic target for oncology. sFLT01 is a novel fusion protein that neutralizes mouse and human PlGF (mPlGF, hPlGF) and mouse and human VEGF-A (mVEGF-A, hVEGF-A). It was tested in syngeneic and xenograft tumor models to evaluate the effects of simultaneously neutralizing PlGF and VEGF-A and to investigate changes observed in the clinic in preclinical models.

DOI: 10.1158/1078-0432.CCR-10-2687
Version: za2963e q8zac q8zbd q8zc2 q8zd3 q8ze7 q8zf0 q8zgd
Buy PDF

Similar articles you may find interesting…

  1. Implications of the presence of N-glycolylneuraminic acid in recombinant therapeutic glycoproteins.
    Darius Ghaderi, Rachel E Taylor, ... Ajit Varki

    Nat Biotechnol 28(8):863-7 (2010) PMID 20657583 PMCID PMC3077421

    We demonstrate the presence of covalently bound Neu5Gc in cetuximab (Erbitux) but not panitumumab (Vectibix). Anti-Neu5Gc antibodies from healthy humans interact with cetuximab in a Neu5Gc-specific manner and generate immune complexes in vitro. Mice with a human-like defect in Neu5Gc synthesis gener...
    View PDF
  2. Evolving concepts of specificity in immune reactions.
    Herman N HN Eisen and Arup K AK Chakraborty

    Audio, Transactions of the IRE Profes... 107(52):22373-80 (2010) PMID 21173256

    We critically consider the mechanistic bases for this specificity/degeneracy enigma and also compare and contrast Ag recognition by Abs and TCRs....
    Buy PDF
  3. Relationship between neuropathology and disease progression in the SOD1^G^9^3^A ALS mouse
    Wendy W Yang, Richard L Sidman, ... Lamya S Shihabuddin

    Exp Neurol 227(2):9 (2011) PMID 21145892

    We examined quantitatively the temporal development of neuropathologic features in the brain and spinal cord of a mouse model of ALS (SOD1(G93A)). Four phases of the disease were studied in both male and female SOD1(G93A) mice: presymptomatic (PRE-SYM), symptomatic (SYM), endstage (ES) and moribund...
    Buy PDF